Canagliflozin: Cui Bono?

Matthew A Cavender^{1

2}, Mikhail Kosiborod^{3

4}

Affiliations

¹ Department of Medicine, University of North Carolina, Chapel Hill (M.A.C.) matt.cavender@unc.edu.
² Department of Medicine, Baim Institute for Clinical Research, Boston, MA (M.A.C.).
³ Department of Medicine, St Luke's Mid America Heart Institute, Kansas City, MO (M.K.).
⁴ Department of Medicine, University of Missouri-Kansas City (M.K.).

Editorial

Matthew A Cavender et al. Circulation. 2018.

. 2018 Jan 23;137(4):335-337.

doi: 10.1161/CIRCULATIONAHA.117.032198. Epub 2017 Nov 13.

Matthew A Cavender^{1

2}, Mikhail Kosiborod^{3

4}

¹ Department of Medicine, University of North Carolina, Chapel Hill (M.A.C.) matt.cavender@unc.edu.
² Department of Medicine, Baim Institute for Clinical Research, Boston, MA (M.A.C.).
³ Department of Medicine, St Luke's Mid America Heart Institute, Kansas City, MO (M.K.).
⁴ Department of Medicine, University of Missouri-Kansas City (M.K.).

No abstract available

Keywords: Editorials; diabetes mellitus, type 2; heart failure; primary prevention; secondary prevention.

Comment on

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group. Mahaffey KW, et al. Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133604 Free PMC article. Clinical Trial.